hotspot -WSS

hotspot

author：hotspot 2025-09-30 15:22:31 - browse：8

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Pumping milk in bathrooms at health conferences is common

focus

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

TikTok, Instagram influencers need more rules for drug ads

Update the Apgar Score to remove skin color

Mass General, Mayo Clinic look to monetize custom

High breast density mammograms need follow

HPV vaccine, cervical cancer study delivers historic results

knowledge

hotspot

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CVS is on a mission to consolidate health care. Will it work?

Continuity nursing helped my family in our darkest PICU moments

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How Vertex's cystic fibrosis drug is changing patients' lives

Medical records are filled with copy

Ukraine and a new approach to mental health in war

Novavax promises a turnaround & Lilly roils the obesity market

Dog Aging Project founders on what lies ahead after losing funding

focus

CDC's new outbreak response network to include Northeastern

Readout LOUD podcast: possible new ALS drug, artificial wombs

There's an unseen cost to disruptive road

Flu vaccine reformulation won't be easy, manufacturers warn

What Congress can do to address the rural doctor shortage

Biotech stock slump in 2023: awaiting the turnaround

focus

hotspot

focus

focus